Global Acute Heart Failure (AHF) Therapeutics Market to Reach $2.9 Billion by 2030
The global market for Acute Heart Failure (AHF) Therapeutics estimated at US$599.7 Million in the year 2022, is projected to reach a revised size of US$2.9 Billion by 2030, growing at a CAGR of 21.7% over the analysis period 2022-2030. Cardiac Glycosides, one of the segments analyzed in the report, is projected to record a 22.3% CAGR and reach US$762.4 Million by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the B-Blockers segment is readjusted to a revised 25.1% CAGR for the next 8-year period.The U.S. Market is Estimated at $163.4 Million, While China is Forecast to Grow at 30.4% CAGR
The Acute Heart Failure (AHF) Therapeutics market in the U.S. is estimated at US$163.4 Million in the year 2022. China, the world's second largest economy, is forecast to reach a projected market size of US$841.2 Million by the year 2030 trailing a CAGR of 30.4% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 16.3% and 18.4% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 17.1% CAGR. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$433.4 Million by the year 2030.Select Competitors (Total 93 Featured) -
- Bayer AG
- Bristol-Myers Squibb Company
- Cardiorentis AG
- CVie Therapeutics Limited
- Cytokinetics, Inc.
- Merck & Co., Inc.
- Novartis AG
- Orion Corporation
- PhaseBio Pharmaceuticals, Inc.
What's New?
- Special coverage on Russia-Ukraine war; global inflation; easing of zero-Covid policy in China and its `bumpy` reopening; supply chain disruptions, global trade tensions; and risk of recession.
- Global competitiveness and key competitor percentage market shares
- Market presence across multiple geographies - Strong/Active/Niche/Trivial
- Online interactive peer-to-peer collaborative bespoke updates
- Access to digital archives and Research Platform
- Complimentary updates for one year
Table of Contents
I. METHODOLOGYII. EXECUTIVE SUMMARYIII. MARKET ANALYSISSOUTH KOREAREST OF ASIA-PACIFICARGENTINABRAZILMEXICOREST OF LATIN AMERICAIRANISRAELSAUDI ARABIAUNITED ARAB EMIRATESREST OF MIDDLE EASTIV. COMPETITION
1. MARKET OVERVIEW
- Influencer Market Insights
- World Market Trajectories
- Market Outlook
- Recent Market Activity
- Sizing the AHF Market
- Acute Heart Failure - An Overview of the Disease and Available Therapeutics
- Diuretics and Vasodilators - The First Line Therapy for AHF
- Other Known Drugs for AHF - Lower Efficacy Thwarts Use
- Acute Heart Failure (AHF) Therapeutics - Global Key Competitors Percentage Market Share in 2022 (E)
- Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2022 (E)
- Impact of Covid-19 and a Looming Global Recession
2. FOCUS ON SELECT PLAYERS
- Bayer AG (Germany)
- Bristol-Myers Squibb Company (USA)
- Cardiorentis AG (Switzerland)
- CVie Therapeutics Limited (Taiwan)
- Cytokinetics, Inc. (USA)
- Merck & Co. (USA)
- Novartis AG (Switzerland)
- Orion Corporation (Finland)
- PhaseBio Pharmaceuticals, Inc. (USA)
3. MARKET TRENDS & DRIVERS
- Conventional Therapies Leave Considerable Unmet Needs
- Novel Treatments Offer a Ray of Hope
- Key AHF Therapeutics in the Pipeline
- Serelaxin Nears Trial Readout form RELAX-AHF-2
- Ularitide - A Novel Drug in Development for AHF
- The Litany of Drug Failures Expands, Emphasis on Prevention Grows
- Other Promising Drugs under Development
- Research Findings
- Kidney Dysfunction - Predictor of Acute Heart failure
- Genetic Influence on Heart Disease among African Americans
- Higher Body Mass Index - A Key Risk Factor for AHF
- Supplemental Oxygen Therapy May not be for All Cases of AHF
- Macro Growth Drivers
- Alarming Levels of Cardiovascular Disease (CVD) Prevalence: Key Growth Driver for AHF Therapeutics
- Ballooning Elderly Population: The Vital Growth Driver for AHF Therapeutics
4. GLOBAL MARKET PERSPECTIVE
- Table 1: World Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
- Table 2: World 8-Year Perspective for Acute Heart Failure (AHF) Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2023 & 2030
- Table 3: World Recent Past, Current & Future Analysis for Cardiac Glycosides by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
- Table 4: World 8-Year Perspective for Cardiac Glycosides by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2023 & 2030
- Table 5: World Recent Past, Current & Future Analysis for B-Blockers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
- Table 6: World 8-Year Perspective for B-Blockers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2023 & 2030
- Table 7: World Recent Past, Current & Future Analysis for Calcium Channel Blockers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
- Table 8: World 8-Year Perspective for Calcium Channel Blockers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2023 & 2030
- Table 9: World Recent Past, Current & Future Analysis for Diuretics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
- Table 10: World 8-Year Perspective for Diuretics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2023 & 2030
- Table 11: World Recent Past, Current & Future Analysis for Other Product Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
- Table 12: World 8-Year Perspective for Other Product Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2023 & 2030
- Table 13: World Recent Past, Current & Future Analysis for Home Care by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
- Table 14: World 8-Year Perspective for Home Care by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2023 & 2030
- Table 15: World Recent Past, Current & Future Analysis for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
- Table 16: World 8-Year Perspective for Hospitals by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2023 & 2030
- Table 17: World Recent Past, Current & Future Analysis for Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
- Table 18: World 8-Year Perspective for Clinics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2023 & 2030
- Table 19: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
- Table 20: World 8-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2023 & 2030
- Table 21: World Acute Heart Failure (AHF) Therapeutics Market Analysis of Annual Sales in US$ Thousand for Years 2012 through 2030
UNITED STATES
- Acute Heart Failure (AHF) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2023 (E)
- Table 22: USA Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by Product Type - Cardiac Glycosides, B-Blockers, Calcium Channel Blockers, Diuretics and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- Table 23: USA 8-Year Perspective for Acute Heart Failure (AHF) Therapeutics by Product Type - Percentage Breakdown of Value Sales for Cardiac Glycosides, B-Blockers, Calcium Channel Blockers, Diuretics and Other Product Types for the Years 2023 & 2030
- Table 24: USA Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by End-Use - Home Care, Hospitals, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- Table 25: USA 8-Year Perspective for Acute Heart Failure (AHF) Therapeutics by End-Use - Percentage Breakdown of Value Sales for Home Care, Hospitals, Clinics and Other End-Uses for the Years 2023 & 2030
CANADA
- Table 26: Canada Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by Product Type - Cardiac Glycosides, B-Blockers, Calcium Channel Blockers, Diuretics and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- Table 27: Canada 8-Year Perspective for Acute Heart Failure (AHF) Therapeutics by Product Type - Percentage Breakdown of Value Sales for Cardiac Glycosides, B-Blockers, Calcium Channel Blockers, Diuretics and Other Product Types for the Years 2023 & 2030
- Table 28: Canada Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by End-Use - Home Care, Hospitals, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- Table 29: Canada 8-Year Perspective for Acute Heart Failure (AHF) Therapeutics by End-Use - Percentage Breakdown of Value Sales for Home Care, Hospitals, Clinics and Other End-Uses for the Years 2023 & 2030
JAPAN
- Acute Heart Failure (AHF) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2023 (E)
- Table 30: Japan Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by Product Type - Cardiac Glycosides, B-Blockers, Calcium Channel Blockers, Diuretics and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- Table 31: Japan 8-Year Perspective for Acute Heart Failure (AHF) Therapeutics by Product Type - Percentage Breakdown of Value Sales for Cardiac Glycosides, B-Blockers, Calcium Channel Blockers, Diuretics and Other Product Types for the Years 2023 & 2030
- Table 32: Japan Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by End-Use - Home Care, Hospitals, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- Table 33: Japan 8-Year Perspective for Acute Heart Failure (AHF) Therapeutics by End-Use - Percentage Breakdown of Value Sales for Home Care, Hospitals, Clinics and Other End-Uses for the Years 2023 & 2030
CHINA
- Acute Heart Failure (AHF) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2023 (E)
- Table 34: China Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by Product Type - Cardiac Glycosides, B-Blockers, Calcium Channel Blockers, Diuretics and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- Table 35: China 8-Year Perspective for Acute Heart Failure (AHF) Therapeutics by Product Type - Percentage Breakdown of Value Sales for Cardiac Glycosides, B-Blockers, Calcium Channel Blockers, Diuretics and Other Product Types for the Years 2023 & 2030
- Table 36: China Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by End-Use - Home Care, Hospitals, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- Table 37: China 8-Year Perspective for Acute Heart Failure (AHF) Therapeutics by End-Use - Percentage Breakdown of Value Sales for Home Care, Hospitals, Clinics and Other End-Uses for the Years 2023 & 2030
EUROPE
- Acute Heart Failure (AHF) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2023 (E)
- Table 38: Europe Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
- Table 39: Europe 8-Year Perspective for Acute Heart Failure (AHF) Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2023 & 2030
- Table 40: Europe Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by Product Type - Cardiac Glycosides, B-Blockers, Calcium Channel Blockers, Diuretics and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- Table 41: Europe 8-Year Perspective for Acute Heart Failure (AHF) Therapeutics by Product Type - Percentage Breakdown of Value Sales for Cardiac Glycosides, B-Blockers, Calcium Channel Blockers, Diuretics and Other Product Types for the Years 2023 & 2030
- Table 42: Europe Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by End-Use - Home Care, Hospitals, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- Table 43: Europe 8-Year Perspective for Acute Heart Failure (AHF) Therapeutics by End-Use - Percentage Breakdown of Value Sales for Home Care, Hospitals, Clinics and Other End-Uses for the Years 2023 & 2030
FRANCE
- Acute Heart Failure (AHF) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2023 (E)
- Table 44: France Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by Product Type - Cardiac Glycosides, B-Blockers, Calcium Channel Blockers, Diuretics and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- Table 45: France 8-Year Perspective for Acute Heart Failure (AHF) Therapeutics by Product Type - Percentage Breakdown of Value Sales for Cardiac Glycosides, B-Blockers, Calcium Channel Blockers, Diuretics and Other Product Types for the Years 2023 & 2030
- Table 46: France Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by End-Use - Home Care, Hospitals, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- Table 47: France 8-Year Perspective for Acute Heart Failure (AHF) Therapeutics by End-Use - Percentage Breakdown of Value Sales for Home Care, Hospitals, Clinics and Other End-Uses for the Years 2023 & 2030
GERMANY
- Acute Heart Failure (AHF) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2023 (E)
- Table 48: Germany Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by Product Type - Cardiac Glycosides, B-Blockers, Calcium Channel Blockers, Diuretics and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- Table 49: Germany 8-Year Perspective for Acute Heart Failure (AHF) Therapeutics by Product Type - Percentage Breakdown of Value Sales for Cardiac Glycosides, B-Blockers, Calcium Channel Blockers, Diuretics and Other Product Types for the Years 2023 & 2030
- Table 50: Germany Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by End-Use - Home Care, Hospitals, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- Table 51: Germany 8-Year Perspective for Acute Heart Failure (AHF) Therapeutics by End-Use - Percentage Breakdown of Value Sales for Home Care, Hospitals, Clinics and Other End-Uses for the Years 2023 & 2030
ITALY
- Table 52: Italy Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by Product Type - Cardiac Glycosides, B-Blockers, Calcium Channel Blockers, Diuretics and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- Table 53: Italy 8-Year Perspective for Acute Heart Failure (AHF) Therapeutics by Product Type - Percentage Breakdown of Value Sales for Cardiac Glycosides, B-Blockers, Calcium Channel Blockers, Diuretics and Other Product Types for the Years 2023 & 2030
- Table 54: Italy Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by End-Use - Home Care, Hospitals, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- Table 55: Italy 8-Year Perspective for Acute Heart Failure (AHF) Therapeutics by End-Use - Percentage Breakdown of Value Sales for Home Care, Hospitals, Clinics and Other End-Uses for the Years 2023 & 2030
UNITED KINGDOM
- Acute Heart Failure (AHF) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2023 (E)
- Table 56: UK Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by Product Type - Cardiac Glycosides, B-Blockers, Calcium Channel Blockers, Diuretics and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- Table 57: UK 8-Year Perspective for Acute Heart Failure (AHF) Therapeutics by Product Type - Percentage Breakdown of Value Sales for Cardiac Glycosides, B-Blockers, Calcium Channel Blockers, Diuretics and Other Product Types for the Years 2023 & 2030
- Table 58: UK Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by End-Use - Home Care, Hospitals, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- Table 59: UK 8-Year Perspective for Acute Heart Failure (AHF) Therapeutics by End-Use - Percentage Breakdown of Value Sales for Home Care, Hospitals, Clinics and Other End-Uses for the Years 2023 & 2030
SPAIN
- Table 60: Spain Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by Product Type - Cardiac Glycosides, B-Blockers, Calcium Channel Blockers, Diuretics and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- Table 61: Spain 8-Year Perspective for Acute Heart Failure (AHF) Therapeutics by Product Type - Percentage Breakdown of Value Sales for Cardiac Glycosides, B-Blockers, Calcium Channel Blockers, Diuretics and Other Product Types for the Years 2023 & 2030
- Table 62: Spain Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by End-Use - Home Care, Hospitals, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- Table 63: Spain 8-Year Perspective for Acute Heart Failure (AHF) Therapeutics by End-Use - Percentage Breakdown of Value Sales for Home Care, Hospitals, Clinics and Other End-Uses for the Years 2023 & 2030
RUSSIA
- Table 64: Russia Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by Product Type - Cardiac Glycosides, B-Blockers, Calcium Channel Blockers, Diuretics and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- Table 65: Russia 8-Year Perspective for Acute Heart Failure (AHF) Therapeutics by Product Type - Percentage Breakdown of Value Sales for Cardiac Glycosides, B-Blockers, Calcium Channel Blockers, Diuretics and Other Product Types for the Years 2023 & 2030
- Table 66: Russia Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by End-Use - Home Care, Hospitals, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- Table 67: Russia 8-Year Perspective for Acute Heart Failure (AHF) Therapeutics by End-Use - Percentage Breakdown of Value Sales for Home Care, Hospitals, Clinics and Other End-Uses for the Years 2023 & 2030
REST OF EUROPE
- Table 68: Rest of Europe Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by Product Type - Cardiac Glycosides, B-Blockers, Calcium Channel Blockers, Diuretics and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- Table 69: Rest of Europe 8-Year Perspective for Acute Heart Failure (AHF) Therapeutics by Product Type - Percentage Breakdown of Value Sales for Cardiac Glycosides, B-Blockers, Calcium Channel Blockers, Diuretics and Other Product Types for the Years 2023 & 2030
- Table 70: Rest of Europe Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by End-Use - Home Care, Hospitals, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- Table 71: Rest of Europe 8-Year Perspective for Acute Heart Failure (AHF) Therapeutics by End-Use - Percentage Breakdown of Value Sales for Home Care, Hospitals, Clinics and Other End-Uses for the Years 2023 & 2030
ASIA-PACIFIC
- Acute Heart Failure (AHF) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2023 (E)
- Table 72: Asia-Pacific Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
- Table 73: Asia-Pacific 8-Year Perspective for Acute Heart Failure (AHF) Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2023 & 2030
- Table 74: Asia-Pacific Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by Product Type - Cardiac Glycosides, B-Blockers, Calcium Channel Blockers, Diuretics and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- Table 75: Asia-Pacific 8-Year Perspective for Acute Heart Failure (AHF) Therapeutics by Product Type - Percentage Breakdown of Value Sales for Cardiac Glycosides, B-Blockers, Calcium Channel Blockers, Diuretics and Other Product Types for the Years 2023 & 2030
- Table 76: Asia-Pacific Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by End-Use - Home Care, Hospitals, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- Table 77: Asia-Pacific 8-Year Perspective for Acute Heart Failure (AHF) Therapeutics by End-Use - Percentage Breakdown of Value Sales for Home Care, Hospitals, Clinics and Other End-Uses for the Years 2023 & 2030
AUSTRALIA
- Acute Heart Failure (AHF) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2023 (E)
INDIA
- Acute Heart Failure (AHF) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2023 (E)
LATIN AMERICA
- Acute Heart Failure (AHF) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2023 (E)
MIDDLE EAST
- Acute Heart Failure (AHF) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2023 (E)
AFRICA
- Acute Heart Failure (AHF) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2023 (E)
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Bayer AG
- Bristol-Myers Squibb Company
- Cardiorentis AG
- CVie Therapeutics Limited
- Cytokinetics, Inc.
- Merck & Co., Inc.
- Novartis AG
- Orion Corporation
- PhaseBio Pharmaceuticals, Inc.
Table Information
Report Attribute | Details |
---|---|
No. of Pages | 299 |
Published | May 2024 |
Forecast Period | 2022 - 2030 |
Estimated Market Value ( USD | $ 599.7 Million |
Forecasted Market Value ( USD | $ 2900 Million |
Compound Annual Growth Rate | 21.8% |
Regions Covered | Global |